Cutaneous mycosis

Summary

Cutaneous mycosis (MONDO:0000254) is a disease (an umbrella term covering 5 Mondo subtypes) with 1 GWAS associations across 6 studies. A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• GWAS associations: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cutaneous mycosis
Mondo ID	MONDO:0000254
DOID	DOID:0050134
SNOMED CT	14560005
Anatomy (UBERON)	UBERON:0002416
Is cancer (heuristic)	no

Data availability: 1 GWAS association (6 studies).

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › cutaneous mycosis

Related subtypes (17): systemic mycosis, fungal esophagitis, opportunistic mycosis, fungal gastritis, fungal lung infectious disease, Pneumocystis infectious disease, sporotrichosis, fungal meningitis, fungal myositis, scedosporiosis, fungal infection of eye, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (5): subcutaneous mycosis, dermatomycosis, tinea infection, superficial mycosis, cutaneous basidiobolomycosis

Genetics & variants

GWAS landscape

1 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr2:190868665	2e-08		G	3.2

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473082	UK Biobank Whole-Genome Sequencing Consortium	2025	5,178	453,262	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667835	UK Biobank Whole-Genome Sequencing Consortium	2025	5,178	453,262	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90726653	Kim HI	2026	4,117	39,909	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.
GCST90079554	Backman JD	2021	880	383,055	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083540	Backman JD	2021	880	383,055	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90473083	UK Biobank Whole-Genome Sequencing Consortium	2025	242	9,371	Whole-genome sequencing of 490,640 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr2:190868665							2e-08	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.